 |
|
|
| |
Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients:
global 48 week results from ANDES Study
|
| |
| |
AIDS 2022 July 29 - Aug 1 Montreal
M.I. Figueroa * (1), O. Sued (1), P. Patterson (1), D. Cecchini (2), M. Sanchez (3), M.J. Rolon (4), G. Lopardo (5), M. Ceschel (1), G. Mernies (1), M. Destefano (1), A. Gun (6), V. Fink (1), Z. Ortiz (7), P. Cahn (7), on behalf ANDES Study Group (1) Fundacion Huesped, Research Department, Ciudad Autónoma de Buenos Aires, Argentina, (2) Hospital Argerich, Infectious Disease Unit, Ciudad de Buenos Aires, Argentina, (3) Hospital Italiano, Infectious Disease Service, Ciudad de Buenos Aires, Argentina, (4) Hospital Juan A Fernandez, Infectious disease Division, Ciudad de Buenos Aires, Argentina, (5) Centro de Estudios Infectologicos SA (CTD Stamboulian), Research Department, Ciudad de Buenos Aires, Argentina, (6) Fundacion Huesped, Laboratory Department, Ciudad Autónoma de Buenos Aires, Argentina, (7) Fundacion Huesped, Research Direction, Ciudad Autónoma de Buenos Aires, Argentina
Regarding lab abnormalities, no significant differences were found. Comparing laboratory values changes between baseline and week 48, we only found differences in the lipid profile, with total cholesterol and LDL-cholesterol being higher in the dual therapy arm; however, these changes did not exceed normal values.
|
| |
|
|
|
|
|
